Search

Displaying results 1281 - 1290 of 3388 in total
  1. Target

    Serotonin Receptors

    go.drugbank.com/bio_entities/BE0004862
    TargetHumans

    Receptor for lasmiditan, a drug for the treatment of acute migraine (PubMed:34239069). … G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1565658, PubMed:1652050, PubMed:33762731).

    Polypeptides: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1BSynonyms: Serotonin receptor 1A, Serotonin receptor 1B
  2. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    both treatment-naive and PI-experienced patients. … TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir].

  3. Drug

    Levetiracetam

    go.drugbank.com/drugs/DB01202
    ApprovedInvestigational

    Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically un...

    Categories: P-glycoprotein substratesProducts: KEPPRA 100MG/ML 10MLDOS PI, KEPPRA 100MG/ML 10ML DOS P
  4. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    Recent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity

    Synonyms: CCK-PZ
  5. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction

  6. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction

  7. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

    Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein inducers, P-glycoprotein substrates
  8. Drug

    PF-03463275

    go.drugbank.com/drugs/DB11993
    Investigational

    PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.

  9. Drug

    Tinlorafenib

    go.drugbank.com/drugs/DB17082
    Investigational

    Tinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of BRAF V600 mutations.[A253992]

  10. Drug

    ATB-346

    go.drugbank.com/drugs/DB15377
    Investigational

    ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).